These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
334 related articles for article (PubMed ID: 27403880)
1. A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload. Sripetchwandee J; Wongjaikam S; Krintratun W; Chattipakorn N; Chattipakorn SC Neuroscience; 2016 Sep; 332():191-202. PubMed ID: 27403880 [TBL] [Abstract][Full Text] [Related]
2. Combined Iron Chelator and Antioxidant Exerted Greater Efficacy on Cardioprotection Than Monotherapy in Iron-Overloaded Rats. Wongjaikam S; Kumfu S; Khamseekaew J; Sripetchwandee J; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N PLoS One; 2016; 11(7):e0159414. PubMed ID: 27428732 [TBL] [Abstract][Full Text] [Related]
3. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine. Wongjaikam S; Kumfu S; Khamseekaew J; Chattipakorn SC; Chattipakorn N Sci Rep; 2017 Mar; 7():44460. PubMed ID: 28287621 [TBL] [Abstract][Full Text] [Related]
4. A combination of an iron chelator with an antioxidant exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice. Kumfu S; Khamseekaew J; Palee S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N Free Radic Res; 2018 Jan; 52(1):70-79. PubMed ID: 29207893 [TBL] [Abstract][Full Text] [Related]
5. Combined therapy of iron chelator and antioxidant completely restores brain dysfunction induced by iron toxicity. Sripetchwandee J; Pipatpiboon N; Chattipakorn N; Chattipakorn S PLoS One; 2014; 9(1):e85115. PubMed ID: 24400127 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy of deferasirox and deferoxamine shows significant improvements in markers of iron overload in a patient with β-thalassemia major and severe iron burden. Voskaridou E; Komninaka V; Karavas A; Terpos E; Akianidis V; Christoulas D Transfusion; 2014 Mar; 54(3):646-9. PubMed ID: 23834310 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572 [TBL] [Abstract][Full Text] [Related]
8. Dual T-type and L-type calcium channel blocker exerts beneficial effects in attenuating cardiovascular dysfunction in iron-overloaded thalassaemic mice. Kumfu S; Chattipakorn SC; Fucharoen S; Chattipakorn N Exp Physiol; 2016 Apr; 101(4):521-39. PubMed ID: 26824522 [TBL] [Abstract][Full Text] [Related]
9. Combination of deferasirox and deferoxamine in clinical practice: an alternative scheme of chelation in thalassemia major patients. Cassinerio E; Orofino N; Roghi A; Duca L; Poggiali E; Fraquelli M; Zanaboni L; Cappellini MD Blood Cells Mol Dis; 2014 Sep; 53(3):164-7. PubMed ID: 24846580 [TBL] [Abstract][Full Text] [Related]
10. Combined iron chelator with N-acetylcysteine exerts the greatest effect on improving cardiac calcium homeostasis in iron-overloaded thalassemic mice. Sumneang N; Kumfu S; Khamseekaew J; Siri-Angkul N; Fucharoen S; Chattipakorn SC; Chattipakorn N Toxicology; 2019 Nov; 427():152289. PubMed ID: 31542421 [TBL] [Abstract][Full Text] [Related]
11. Destructive effect of iron overload in brain tissue of albino rats: Ameliorative role of silver immobilized organo-modified casein nanocomposite as co-treating agent with Deferasirox. Adel RM; Lotfy RA; Darwish AS; Amer AS J Trace Elem Med Biol; 2021 Sep; 67():126794. PubMed ID: 34052583 [TBL] [Abstract][Full Text] [Related]
12. Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization. Vlachodimitropoulou Koumoutsea E; Garbowski M; Porter J Br J Haematol; 2015 Sep; 170(6):874-83. PubMed ID: 26033030 [TBL] [Abstract][Full Text] [Related]
13. Comparative study of the protective effect between deferoxamine and deferiprone on chronic iron overload induced cardiotoxicity in rats. Emara AM; El Kelany RS; Moustafa KA Hum Exp Toxicol; 2006 Jul; 25(7):375-85. PubMed ID: 16898166 [TBL] [Abstract][Full Text] [Related]
14. Objectives and mechanism of iron chelation therapy. Hershko C; Link G; Konijn AM; Cabantchik ZI Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658 [TBL] [Abstract][Full Text] [Related]
15. Activation of the molecular and functional effects of Nrf2 against chronic iron oxide nanorod overload-induced cardiotoxicity. Elgharabawy RM; Elgharbawy DM; Emara AM Hum Exp Toxicol; 2018 Aug; 37(8):870-885. PubMed ID: 29172713 [TBL] [Abstract][Full Text] [Related]
16. Iron chelator deferiprone rescues memory deficits, hippocampal BDNF levels and antioxidant defenses in an experimental model of memory impairment. Alcalde LA; de Freitas BS; Machado GDB; de Freitas Crivelaro PC; Dornelles VC; Gus H; Monteiro RT; Kist LW; Bogo MR; Schröder N Biometals; 2018 Dec; 31(6):927-940. PubMed ID: 30117045 [TBL] [Abstract][Full Text] [Related]
17. The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amyloid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer's Disease. Banerjee P; Sahoo A; Anand S; Bir A; Chakrabarti S J Alzheimers Dis; 2016; 49(3):681-93. PubMed ID: 26484920 [TBL] [Abstract][Full Text] [Related]
18. Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow. Shen JC; Zhang YC; Zhao MF Braz J Med Biol Res; 2017 Oct; 50(12):e6087. PubMed ID: 29069221 [TBL] [Abstract][Full Text] [Related]
19. Combined iron chelator and T-type calcium channel blocker exerts greater efficacy on cardioprotection than monotherapy in iron-overload thalassemic mice. Kumfu S; Khamseekaew J; Palee S; Srichairatanakool S; Fucharoen S; Chattipakorn SC; Chattipakorn N Eur J Pharmacol; 2018 Mar; 822():43-50. PubMed ID: 29366843 [TBL] [Abstract][Full Text] [Related]